Q/C Technologies amended terms governing its Series G and Series H preferred stock and certain warrants held by PharmaCyte Biotech, a holder of at least a majority of each preferred series. The changes cover amendment procedures and beneficial-ownership limits. Separately, the company finalized a previously agreed six-month extension to the Series H preferred stock’s maturity date.
- Series G and Series H terms: Amendments to both preferred-stock designations revised provisions governing how their terms may be amended and changed the beneficial-ownership limits applicable to PharmaCyte. The company also amended the amendment and beneficial-ownership-limit provisions in PharmaCyte’s Series G long-term warrants.
- Series H maturity extended: The maturity date moved from March 2, 2027, to September 2, 2027. PharmaCyte had consented to this change on November 15; the amendment took effect when the company filed it on November 20.
- PharmaCyte’s role: Because PharmaCyte holds at least a majority of the outstanding shares of both preferred series, it qualifies as the required holder for amendments to those terms.
- What is not specified: The announcement does not state the revised ownership-limit percentages or describe the detailed changes to amendment procedures. It does not identify a new financing or a change to the Series G preferred stock’s maturity.
The maturity extension gives the Series H preferred stock an additional six months before it comes due. The ownership-limit changes affect the terms applicable to PharmaCyte, but their precise effect cannot be determined without the amended provisions.
